Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Profitability
This table compares Autonomix Medical and Pacific Biosciences of California’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -228.82% | -186.65% |
| Pacific Biosciences of California | -341.47% | -326.43% | -19.40% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Autonomix Medical and Pacific Biosciences of California, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
| Pacific Biosciences of California | 2 | 2 | 1 | 0 | 1.80 |
Volatility & Risk
Autonomix Medical has a beta of -2.48, suggesting that its stock price is 348% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500.
Valuation & Earnings
This table compares Autonomix Medical and Pacific Biosciences of California”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($3.55) | -0.10 |
| Pacific Biosciences of California | $160.01 million | 2.94 | -$546.38 million | ($1.84) | -0.85 |
Autonomix Medical has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
10.8% of Autonomix Medical shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Autonomix Medical beats Pacific Biosciences of California on 8 of the 12 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
